Literature DB >> 19886798

The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.

Giovanna Travi1, Steven A Pergam, Hu Xie, Paul Carpenter, Hans-Peter Kiem, Lawrence Corey, Michael J Boeckh.   

Abstract

In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation in a cohort of hematopoietic cell transplant recipients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19886798      PMCID： PMC2779734          DOI： 10.1086/648120

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

Authors:  Sabine Mumprecht; Matthias Matter; Viktor Pavelic; Adrian F Ochsenbein
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

2.  Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour.

Authors:  M A Durosinmi; P O Ogbe; L Salawu; A A Oyekunle
Journal:  Singapore Med J       Date:  2007-01       Impact factor: 1.858

3.  Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.

Authors:  Ruth Seggewiss; Karin Loré; Elisabeth Greiner; Magnus K Magnusson; David A Price; Daniel C Douek; Cynthia E Dunbar; Adrian Wiestner
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

4.  Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

Authors:  Juan Luis Steegmann; Gemma Moreno; Concepción Aláez; Santiago Osorio; Asunción Granda; Rafael de la Cámara; Eva Arranz; Fernando Gómez Reino; Francisco Rodriguez Salvanés; José María Fernández-Rañada; Cecilia Muñoz
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

5.  Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

Authors:  Silke Appel; Andreas M Boehmler; Frank Grünebach; Martin R Müller; Anette Rupf; Markus M Weck; Ulrike Hartmann; Volker L Reichardt; Lothar Kanz; Tim H Brümmendorf; Peter Brossart
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

6.  Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.

Authors:  Hongwei Wang; Fengdong Cheng; Alex Cuenca; Pedro Horna; Zheng Zheng; Kapil Bhalla; Eduardo M Sotomayor
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

7.  Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection.

Authors:  Liliana Soroceanu; Armin Akhavan; Charles S Cobbs
Journal:  Nature       Date:  2008-08-13       Impact factor: 49.962

8.  Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.

Authors:  Hirohisa Nakamae; Katharine A Kirby; Brenda M Sandmaier; Lalita Norasetthada; David G Maloney; Michael B Maris; Chris Davis; Lawrence Corey; Rainer Storb; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-16       Impact factor: 5.742

9.  One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.

Authors:  Veronique Erard; Katherine A Guthrie; Cara Varley; Judson Heugel; Anna Wald; Mary E D Flowers; Lawrence Corey; Michael Boeckh
Journal:  Blood       Date:  2007-05-21       Impact factor: 22.113

10.  Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

Authors:  Gloria N Mattiuzzi; Jorge E Cortes; Moshe Talpaz; James Reuben; Mary Beth Rios; Jianjin Shan; Dimitrios Kontoyiannis; Francis J Giles; Issam Raad; Srdan Verstovsek; Alessandra Ferrajoli; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531
View more
  2 in total

1.  Cytomegalovirus: pathogen, paradigm, and puzzle.

Authors:  Michael Boeckh; Adam P Geballe
Journal:  J Clin Invest       Date:  2011-05       Impact factor: 14.808

2.  The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication.

Authors:  Martin Michaelis; Christina Paulus; Nadine Löschmann; Stephanie Dauth; Elisabeth Stange; Hans Wilhelm Doerr; Michael Nevels; Jindrich Cinatl
Journal:  Cell Mol Life Sci       Date:  2010-08-30       Impact factor: 9.261
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.